Clinical case of Mitochondrial DNA Depletion

The article reports clinical case of early neonatal manifestation of a rare genetic disease – mitochondrial DNA depletion syndrome, confirmed in laboratory in Russia. Mutations of FBXL4, which encodes an orphan mitochondrial F-box protein, involved in the maintenance of mitochondrial DNA (mtDNA), ultimately leading to disruption of mtDNA replication and decreased activity of mitochondrial respiratory chain complexes. It’s a reason of abnormalities in clinically affected tissues, most of all the muscular system and the brain. In our case hydronephrosis on the right, subependimal cysts of the brain, partial intestinal obstruction accompanied by polyhydramnios were diagnosed antenatal. Baby’s condition at birth was satisfactory and worsened dramatically towards the end of the first day of life. Clinical presentation includes sepsis-like symptom complex, neonatal depression, muscular hypotonia, persistent decompensated lactic acidosis, increase in the concentration of mitochondrial markers in blood plasma and urine, and changes in the basal ganglia of the brain. Imaging of the brain by magnetic resonance imaging (MRI) demonstrated global volume loss particularly the subcortical and periventricular white matter with significant abnormal signal in bilateral basal ganglia and brainstem with associated delayed myelination. Differential diagnosis was carried out with hereditary diseases that occur as a «sepsis-like» symptom complex, accompanied by lactic acidosis: a group of metabolic disorders of amino acids, organic acids, β-oxidation defects of fatty acids, respiratory mitochondrial chain disorders and glycogen storage disease. The diagnosis was confirmed after sequencing analysis of 62 mytochondrial genes by NGS (Next Generation Sequencing). Reported disease has an unfavorable prognosis, however, accurate diagnosis is very important for genetic counseling and helps prevent the re-birth of a sick child in the family.

1. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283: 1482–1488.

2. Pfeffer G., Majamaa K., Turnbull D.M., Thorburn D., Chinnery P.F. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; 4: 1–42. DOI: 10.1002/14651858.CD004426.pub3

3. Maypek E. Inborn Errors of Metabolism – Early Detection, Key Symptoms and Therapeutic Options. Bremen. UNI-MED, 2008; 128.

4. Schaefer A.M., Taylor R.W., Turnbull D.M., Chinnery P.F. The epidemiology of mitochondrial disorders–past, present and future. Biochim Biophys Acta 2004; 1659: 115–120.

5. Honzik T., Tesarova M., Magner M., Mayr J., Jesina Р. et al. Neonatal onset of mitochondrial disorders in 129 patients: clinical and laboratory characteristics and a new approach to diagnosis. J Inherit Metab Dis 2012; 35: 749–759. DOI 10.1007/s10545-011-9440-3

6. Gibson K., Halliday J.L., Kirby D.M., Yaplito-Lee J., Thorburn D.R., Boneh A. Mitochondrial oxidative phosphorylation disorders presenting in neonates: clinical manifestations and enzymatic and molecular diagnoses. Pediatrics 2015; 122: 1003–1008. DOI: 10.1542/peds.2007-3502

7. Debray F.G., Lambert M., Mitchell G.A. Disorders of mitochondrial function. Curr Opin Pediatr 2008; 20: 471–482. DOI: 10.1097/MOP.0b013e328306ebb6

8. Van Rij M.C., Jansen F.A.R., Hellebrekers D.M.E.I., Onkenhout W., Smeets H.J.M., Hendrickx A.T. et al. Polyhydramnios and cerebellar atrophy: a prenatal presentation of mitochondrial encephalomyopathy caused by mutations in the FBXL4 gene. Clin Case Rep 2016; 4 (4): 425–428. DOI: 10.1002/ccr3.511

9. Koene S., Smeitink J. Mitochondrial medicine. A clinical guideline. First edition. Netherlands. Khondrion, Nijmegen, 2011; 135.

10. Крылова Т.Д., Прошлякова Т.Ю., Байдакова Г.В., Иткис Ю.С., Куркина М.В., Захарова Е.Ю. Биомаркеры в диагностике и мониторинге лечения болезней клеточных органелл. Медицинская генетика 2016; 15 (7): 3–10. [Krylova T.D., Proshlyakova T.Yu., Baydakova G.V., Itkis Yu.S., Kurkina M.V., Zakharova E.Yu. Biomarkers in diagnosis and treatment monitoring for the cell organelles diseases. Meditsinskaya genetika 2016; 15 (7): 3–10. (in Russ)]

11. Liang C., Ahmad K., Sue C.M. The broadening spectrum of mitochondrial disease: Shifts in the diagnostic paradigm. Biochim Biophys Acta 2014; 1840 (4): 1360–1367. DOI: 10.1016/j.bbagen.2013.10.040

12. Davis R., Liang C., Edema-Hildebrand F., Riley C., Needham M. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology. Amer Acad Neurol 2013; 81: 1819–1826. DOI: 10.1212/01.wnl.0000436068.43384.ef

13. Pagliarini D.J., Calvo S.E., Chang B., Sheth S.A., Vafai S.B., Ong S.E. et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008; 134 (1): 112–123. DOI: 10.1016/j.cell.2008.06.016

14. Даниленко Н.Г., Цыганкова П.Г., Сивицкая Л.Н., Левданский О.Д., Давыденко О.Г. Синдромы митохондриальной деплеции в неврологической практике: клинические особенности и ДНК-диагностика. Неврология и нейрохирургия (Восточная Европа) 2013; 19 (3): 97–111. [Danilenko N.G., Tsigankova P.G., Sivickaya L.N., Levdansky O.D., Davidenko O.G. Syndromes of mitochondrial deplation in neurological practice: clinical features and DNA diagnostics. Nevrologiya i nejrokhirurgiya ( Eastern Europe) 2013; 19 (3): 97–111. (in Russ)]

15. El-Hattab A.W., Craigen W.J., Scaglia F. Mitochondrial DNA maintenance defects. Biochim Biophys Acta 2017; 1863 (6): 1539–1555. DOI: 10.1016/j.bbadis.2017.02.017

16. Дегтярева А.В., Захарова Е.Ю., Цыганкова П.Г., Чеглецова Е.В., Готье С.В., Цырюльникова О.М. Недостаточность митохондриальной деоксигуанозинкиназы. Вестник Российского государственного медицинского университета 2009; 1: 27–30. [Degtyareva A.V., Zakharova E.Yu., Tsygankova P.G., Chegletsova E.V., Gotye S.V., Tsyrulnikova O.M. Mitochondrial deoxyguanosine kinase deficiency. Vestnik Rossijskogo gosudarstvennogo meditsinskogo universiteta 2009; 1: 27–30. (in Russ)]

17. Михайлова С.В., Захарова Е.Ю., Цыганкова П.Г., Абрукова А.В. Клинический полиморфизм митохондриальных энцефаломиопатий, обусловленных мутациями гена полимеразы гамма. Рос вестн пед и перинатол 2012; 57: 4(2): 54–61. [Mikhailova S.V., Zakharova E.Yu., Tsygankova P.G., Abrukova A.V., Politova E.A. Clinical polymorphism of mitochondrial encephalomyopathies caused by polymerase gamma gene mutations. Ros Vestn Perinatol i Pediatr 2012; 57: 4(2): 54–61. (in Russ)]

18. Bonnen P.E., Yarham J.W., Besse A., Wu P., Faqeih E.A., Al-Asmari A.M. et al. Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. Am J Hum Genet 2013; 93: 471–481. DOI: 10.1016/j.ajhg.2013.07.017

19. Gai X., Ghezzi D., Johnson M.A., Biagosch C.A., Shamseldin H.E., Haack T.B. et al. Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy. Am J Hum Genet 2013; 93: 482–495. DOI: 10.1016/j.ajhg.2013.07.016

20. Huemer M., Karall D., Schossig A., Abdenur J.E. Clinical, morphological, biochemical, imaging and outcome parameters in 21 individuals with mitochondrial maintenance defect related to FBXL4 mutations. J Inherit Metab Dis 2015; 38 (5): 905–914. DOI:10.1007/s10545-015-9836-6

21. Antoun G., McBride S., Vanstone J., Naas T., Michaud J., Redpath S. Detailed Biochemical and Bioenergetic Characterization of FBXL4-Related Encephalomyopathic Mitochondrial DNA Depletion. JIMD Reports 2016; 27: 1–9. DOI: 10.1007/8904_2015_491

22. Barоy T., Pedurupillay C., Bliksrud Y., Rasmussen M., Holmgren A., Vigeland M.D. et al. A novel mutation in FBXL4 in a Norwegian child with encephalomyopathic mitochondrial DNA depletion syndrome 13. Eur J Med Genet 2016; 59; 342–346. DOI: 10.1016/j.ejmg.2016.05.005

23. Winston J. T., Koepp D. M., Zhu C., Elledge S. J., Harper J. W. et al. A family of mammalian F-box proteins. Curr Biol 1999; 9: 1180–1182

24. Nirupam N., Nangia S., Kumar A., Saili A. An unusual case of hyperlactataemia in a neonate. Intern J STD & AIDS 2012; 24 (12): 986–988. DOI: 10.1177/0956462413487326

25. Lefevere M.F., Verhaeghe B.J., Declerck D.H., Van Bocxlaer J.F., De Leenheer A.P., De Sagher R.M. Metabolic Profiling of Urinary Organic Acids by Single and Multicolumn Capillary Gas Chromatography. J Chromatogr Sci 1989; 27 (1): 23–29.

26. Mroch A.R., Laudenschlager M., Flanagan J.D. Detection of a novel FH whole gene deletion in the propositus leading to subsequent prenatal diagnosis in a sibship with fumarase deficiency. Am J Med Genet Part A 2012; 158A: 155–158. DOI: 10.1002/ajmg.a.34344

27. Dashe J., McIntire R.D., Ramus R., Santos-Ramos, Twickler D.M. Hydramnios: anomaly prevalence and sonographic detection. Obstet Gynecol 2002; 100: 134–139.

28. Raju G.P., Li H.C., Bali D., Chen Y.T., Urion D.K., Lidov H.G. et al. A case of congenital glycogen storage disease type IV with a novel GBE1 mutation. J Child Neurol 2008; 23: 349– 352. DOI: 10.1177/0883073807309248

29. Montero R., Yubero D., Villarroya J., Henares D., Jou C., Rodríguez M.A., Ramos F. et al. GDF-15 Is Elevated in Children with Mitochondrial Diseases and Is Induced by Mitochondrial Dysfunction. PLoS ONE 2016; 11 (2): e0148709.

30. Dimmock D.P., Lawlor M.W. Presentation and Diagnostic Evaluation of Mitochondrial Disease. Pediatr Clin North Am 2017; 64 (1): 161–171. DOI: 10.1016/j.pcl.2016.08.011.